前列腺癌患者雄激素剥夺治疗与痴呆风险
基于英国临床实践研究数据链的队列研究纳入30903例新诊断非转移性前列腺癌男性,随访至2016年4月30日。与未使用相比,雄激素剥夺治疗(ADT)与痴呆风险升高无关(调整后HR 1.02,95%CI 0.87-1.19)。
要点
- ADT使用与未使用者痴呆发病率分别为7.4/1000人年与4.4/1000人年,调整后HR 1.02(95%CI 0.87-1.19)。
- 累积使用时长(异质性P=.78)及任一ADT类型均与痴呆风险升高无关。
- 平均随访4.3年(标准差3.6)期间新诊断痴呆799例,发病率6.0/1000人年(95%CI 5.6-6.4)。
核心结论
- 在这项基于人群的研究中,ADT使用与痴呆风险升高无关,但需在不同环境中进一步研究以确认这些发现。
研究设计与样本
- 使用英国临床实践研究数据链构建队列,纳入1988年4月1日至2015年4月30日新诊断非转移性前列腺癌男性30903例,观察至2016年4月30日。
- 采用时间依赖性Cox比例风险模型估计ADT使用与未使用相比的痴呆调整风险比及95%CI,ADT暴露滞后1年。
主要发现
- 平均(标准差)随访4.3(3.6)年期间,新诊断痴呆799例,发病率为6.0/1000人年(95%CI 5.6-6.4)。
- 与未使用相比,ADT使用与痴呆风险升高无关:发病率7.4/1000人年 vs 4.4/1000人年,调整后HR 1.02(95%CI 0.87-1.19)。
- 次要分析中,累积使用时长(异质性P=.78)及任一ADT类型均与痴呆风险升高无关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Recent observational studies have associated the use of androgen deprivation therapy (ADT) with an increased risk of dementia and Alzheimer's disease, but these studies had limitations. The objective of this study was to determine whether the use of ADT is associated with an increased risk of dementia, including Alzheimer's disease, in patients with prostate cancer. Patients and Methods Using the United Kingdom's Clinical Practice Research Datalink, we assembled a cohort of 30,903 men newly diagnosed with nonmetastatic prostate cancer between April 1, 1988 and April 30, 2015, and observed them until April 30, 2016. Time-dependent Cox proportional hazards models were used to estimate adjusted hazard ratios with 95% CIs of dementia associated with the use of ADT compared with nonuse. ADT exposure was lagged by 1 year to account for delays associated with the diagnosis of dementia and to minimize reverse causality. Secondary analyses assessed whether the risk varied with cumulative duration of use and by ADT type. Results During a mean (standard deviation) follow-up of 4.3 (3.6) years, 799 patients were newly diagnosed with dementia (incidence, 6.0; 95% CI, 5.6 to 6.4) per 1,000 person-years. Compared with nonuse, ADT use was not associated with an increased risk of dementia (incidence, 7.4 v 4.4 per 1,000 person-years, respectively; adjusted hazard ratio, 1.02; 95% CI, 0.87 to 1.19). In secondary analyses, cumulative duration of use ( P for heterogeneity = .78) and no single type of ADT were associated with an increased risk of dementia. Conclusion In this population-based study, the use of ADT was not associated with an increased risk of dementia. Additional studies in different settings are needed to confirm these findings.
引用
- Khosrow-Khavar F, Rej S, Yin H, et al. Androgen Deprivation Therapy and the Risk of Dementia in Patients With Prostate Cancer. J Clin Oncol. 2016. PMID: 27870566
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。